The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
In CHB patients receiving Peg-IFN-based therapy, concurrent MASLD may impede the reduction of HBV DNA levels, delay the time of first CVR, and potentially accelerate liver fibrosis progression.
Authors
- Jiaxin Han (ORCID: https://orcid.org/0009-0006-8985-5022)
- Liang Xu
- Liang Xu
- Lianxin Xu
Institutions
- Tianjin Third Central Hospital (CN)
- Tianjin People's Hospital (CN)
- Tianjin Fourth Central Hospital (CN)
- Tianjin Central Hospital of Gynecology Obstetrics (CN)
- Second Hospital of Tianjin Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1708909
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 31.52
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City